Skip to main content
OpenTrials
Completed

NCT Number: NCT02242357

Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension

Study to evaluate efficacy and tolerability of Micardis®/Micardis® Plus under usual daily-practice prescribing conditions in hypertensive patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females for whom a medical antihypertensive therapy is indicated
  • Age >= 18 years

Exclusion criteria

  • Age < 18 years

Treatment and study plan

Micardis®

Drug

Micardis® plus

Drug

Primary outcomes

  1. Change in morning blood pressure (office and self-measured)

    Time frame: up to 6 weeks

Secondary outcomes

  1. Change in heart rate

    Time frame: up to 6 weeks

  2. Number of patients with adverse drug reactions

    Time frame: up to 6 weeks

  3. Assessment of efficacy by investigator on a 5-point scale

    Time frame: at week 6

  4. Assessment of tolerability by investigator on 5-point scale

    Time frame: at week 6

  5. Change in rate of morning complaints

    Time frame: up to 6 weeks

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Post-Marketing Surveillance Study Micardis® Plus

Important dates

Study start
2003
Primary completion
2003
First posted
Sep 17, 2014
Registry last updated
Sep 17, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.